Aurinia to Attend 2024 Jefferies Global Healthcare Conference

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH), a biopharmaceutical company dedicated to delivering treatments for autoimmune diseases, has announced its participation in the 2024 Jefferies Global Healthcare Conference. The event will be held in New York from June 4-6, 2024.

Aurinia's management team is scheduled to engage in one-on-one meetings with investors throughout the conference. Additionally, they will present on Wednesday, June 5, from 8:00 to 8:25 AM Eastern Time. For those unable to attend in person, a live webcast of the presentation will be accessible via the Investor section of Aurinia’s official website.

Aurinia Pharmaceuticals, with its head office located in Edmonton, Alberta, and its U.S. commercial office in Rockville, Maryland, operates as a fully integrated biopharmaceutical entity. The company is particularly focused on providing therapeutic solutions for individuals suffering from autoimmune diseases that have significant unmet medical needs.

In January 2021, Aurinia achieved a significant milestone by launching LUPKYNIS® (voclosporin). This drug is notable for being the first FDA-approved oral therapy specifically designed for adult patients dealing with active lupus nephritis, an autoimmune disease that causes kidney inflammation. LUPKYNIS® represents a breakthrough in treatment options for this patient population, underscoring Aurinia's commitment to addressing critical healthcare gaps.

Aurinia is dedicated to expanding its development efforts on a global scale, aiming to bring innovative solutions to those in need. The company continues to leverage its expertise and resources to improve the quality of life for patients with challenging autoimmune conditions.